Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases

PIONEER study expands the investigation of atacicept into a broad definition of IgA nephropathy and into multiple autoimmune glomerular diseases, supported by the disease-modifying potential of BAFF/APRIL dual inhibition; Multiple regulatory and clinical milestones expected over the next 18 months; Announcements made at Vera's R&D Day in New York, where the company's management team was joined by academic leaders Jonathan Barratt, Richard Lafayette, and Brad Rovin BRISBANE, Calif., Oct. 02, 2024 (GLOBE NEWS ...